Rie Nishi

Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Polyamine Inhibitor SAM486A Augments Cytarabine Cytotoxicity in Methylthioadenosine Phosphorylase-deficient Leukemia Cells.

Polyamine Inhibitor SAM486A Augments Cytarabine Cytotoxicity in Methylthioadenosine Phosphorylase-deficient Leukemia Cells.

Journal: Anticancer research
Published: August 29, 2023

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.

Journal: BMC cancer
Published: July 21, 2020

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.

Journal: BMC cancer
Published: June 11, 2020

High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.

High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.

Journal: Hematological oncology
Published: June 07, 2019

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.

Journal: Cancer science
Published: February 17, 2016

Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.

Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.

Journal: Anticancer research
Published: October 03, 2014

A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.

A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.

Journal: Anticancer research
Published: September 10, 2014

Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.

Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.

Journal: Anticancer research
Published: April 03, 2014

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.

Journal: BMC cancer
Published: February 11, 2014

Variation of urate transport in the nephrons in subtypes of hyperuricemia.

Variation of urate transport in the nephrons in subtypes of hyperuricemia.

Journal: Nephron extra
Published: September 21, 2013

Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.

Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.

Journal: Cancer science
Published: August 23, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026